DM5

IDARUBICIN

Find entries where: DM5

is present as a standalone ligand in 5 entries

Find related ligands:

Chemical Component Summary
Name	IDARUBICIN
Synonyms	4-DEMETHOXY-DAUNORUBICIN
Identifiers	(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-9-ethanoyl-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Formula	C₂₆ H₂₇ N O₉
Molecular Weight	497.494
Type	NON-POLYMER
Isomeric SMILES	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5ccccc5C4=O)O)(C(=O)C)O)N)O
InChI	InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
InChIKey	XDXDZDZNSLXDNA-TZNDIEGXSA-N

Chemical Details
Formal Charge	0
Atom Count	63
Chiral Atom Count	6
Bond Count	67
Aromatic Bond Count	12

Drug Info: DrugBank

DrugBank ID	DB01177 ?
Name	Idarubicin
Groups	approved
Description	An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Synonyms	(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside 4-Demethoxydaunomycin Idarubicin Idarubicinum Idarubicin hydrochloride Idarubicine 4-Demethoxydaunorubicin Idarubicina
Brand Names	Idamycin - Cap 25mg Idarubicin Hydrochloride Idarubicin Hydrochloride Injection Idarubicin Idamycin - Cap 10mg Idamycin - Cap 5mg Aj-idarubicin Idamycin Powder -5mg/vial Idamycin Pws 10mg/vial Idamycin PFS Idamycin Pws 5mg/vial Idamycin Idamycin Powder -10mg/vial
Indication	For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
Categories	Anthracycline Topoisomerase Inhibitor Anthracyclines Anthracyclines and Related Substances Antibiotics, Antineoplastic Antineoplastic Agents Antineoplastic and Immunomodulating Agents Carbohydrates Cardiotoxic antineoplastic agents Cytochrome P-450 CYP2C9 Substrates Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Substrates Cytotoxic Antibiotics and Related Substances Enzyme Inhibitors Glycosides Immunosuppressive Agents Myelosuppressive Agents Naphthacenes Narrow Therapeutic Index Drugs Topoisomerase II Inhibitors Topoisomerase Inhibitors
ATC-Code	L01DB06
CAS number	58957-92-9

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
DNA	-	unknown	intercalation
DNA topoisomerase 2-alpha	MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTY...	unknown	inhibitor
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	substrate
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	substrate
Multidrug resistance-associated protein 1	MALRGFCSADGSDPLWDWNVTWNTSNPDFTKCFQNTVLVWVPCFYLWACF...	unknown	inhibitor

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682